Biopharmaceutical company Invivyd Inc (Nasdaq:IVVD) on Friday reported data showing continued in vitro activity of its mAb candidate, VYD222 (pemivibart), against prevalent SARS-CoV-2 variants, including KP.1.1 FLiRT and KP.3.
These variants are projected to become dominant strains.
The data aligns with independent research suggesting VYD222's effectiveness against these variants.
Invivyd's next mAb candidate, VYD2311, also shows promise against these strains.
Galderma's nemolizumab recommended for NHS funding in England and Wales for atopic dermatitis
Merck launches Phase 3 trial for dengue vaccine candidate V181
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Mezzion Pharma obtains USD20m funding for udenafil Phase 3 clinical development for Fontan patients
UCB announces BIMZELX (bimekizumab-bkzx) three-year data at EULAR 2025
US FDA approves expanded indication for AbbVie's MAVYRET (glecaprevir/pibrentasvir) in acute HCV
MaxCyte and Ori Biotech partner to advance autologous cell therapy manufacturing
OptiBiotix announces publication of positive SlimBiome study in European Journal of Nutrition
Crossject advances paediatric development of ZEPIZURE Junior for epilepsy crisis management
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies